Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 5Melanoma 3Neoplasm Metastasis 2Lung Neoplasms 2Head and Neck Neoplasms 2Glioblastoma 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lymphoma 1Glioma 1Extensive Stage Small Cell Lung Carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 105Specimen Handling 55Magnetic Resonance Spectroscopy 48Biopsy 47Nivolumab 40Paclitaxel 35Gemcitabine 30Radiosurgery 29Carboplatin 28Irinotecan 22Ipilimumab 22Cyclophosphamide 22Cisplatin 22trastuzumab deruxtecan 21Leucovorin 19Capecitabine 19Fluorouracil 18Cetuximab 18Bevacizumab 18130-nm albumin-bound paclitaxel 18Pemetrexed 17Fulvestrant 17Drug Therapy 16Docetaxel 16Taxes 15Oxaliplatin 15olaparib 14abemaciclib 14Radiotherapy 14palbociclib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × epacadostat × 1 year × Clear all
NCT04463771 2025-12-10

POD1UM-204

Incyte Corporation

Phase 2 Active not recruiting
206 enrolled
Gynecologic

Neoplasm Metastasis, Endometrial Neoplasms

NCT02959437 2025-10-21

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

Incyte Corporation

Phase 1/2 Terminated
70 enrolled 14 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡